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7.1  Introduction 
Heart disease is the leading cause of death in the United  States, and 
acute myocardial  infarctions (AMIs), or, more  colloquially, “heart at- 
tacks,” are directly or indirectly responsible for most of these deaths. In 
Japan, as in the United States, heart disease has become one of the signifi- 
cant causes of death. Approximately more than one-third of those with 
heart diseases died of AM1 in 1998 (the death ratios per 0.1 million caused 
by AM1 are 43.3 formales, 34.3 for females, and 38.7 for both sexes; Health 
and Welfare Statistics Association 2000). Though death from AM1 re- 
mains less common in Japan than in the United States, the increasing inci- 
dence of AM1 and the overall aging of Japanese society suggests that heart 
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attacks may become a significant health problem in the future, much as 
cancer is now. 
This study had several main objectives. The first was to create a data set 
containing information on treatments and outcomes among AM1 patients 
in Japan, comparable to the Cooperative Cardiovascular Project (CCP)' in 
the United States. The CCP is a major policy initiative to improve the qual- 
ity of care for Medicare beneficiaries with AM1 undertaken by the Health 
Care Financing Administration (currently called the Center for Medicare 
and Medicaid Services). The second objective was to investigate variation 
between the United States and Japan in the quality of health care for el- 
derly patients (age sixty-five or over) with AMI, with respect to treatments 
and outcomes and controlling for chart-based detailed clinical informa- 
tion. In this study, we  divide medical procedures performed on AM1 pa- 
tients into high-tech and low-tech treatments. We  define high-tech treat- 
ments as those with large fixed or marginal costs and low-tech treatments as 
those with relatively low fixed and marginal costs. Low-tech treatments, in 
principle, could be provided by virtually any medical facility (McClellan 
and Noguchi 1998). Both types of procedures are used widely enough to 
contribute substantially to patient outcomes and hospital expenditure. 
This paper is organized as follows. Section 7.2 reviews related previous 
research.  Section 7.3 justifies the empirical specification we  use in this 
study. Section 7.4 describes the data on patient characteristics and treat- 
ments received. Section 7.5 uses a bivariate probit procedure to investigate 
the determinants of patient outcomes and hospital expenditure, mainly fo- 
cusing on treatment differences. Section 7.6 discusses our findings and 
concludes. 
7.2  Previous Research 
Cardiac catheterization,  a procedure that visualizes blood flow to the 
heart muscle through continuous radiologic images of the flow of dye in- 
jected into the coronary arteries, is the first step for an important set of 
high-tech intensive treatments for heart attack. If this procedure detects 
substantial blockages, it may be followed by a revascularization procedure 
1. During the national phase of the CCP project, HCFA conducted standardized abstrac- 
tions of the medical records of all Medicare beneficiaries hospitalized  with AM1 over an 
eight-month period at essentially all hospitals in the United States that had not participated 
in a four-state pilot phase. The eight-month sampling frame was continuous at each hospital, 
and all sampling occurred between April 1994  and July 1995. Marciniak et al. (1998) provide 
more details on CCP goals, sampling and data collection strategy, and methods used to assure 
standardization and completeness of the medical record reviews. Altogether, charts were ab- 
stracted for approximately 180,000 AM1 patients. These data were linked to Medicare ad- 
ministrative records (enrollment and hospitalization files), which have been used in previous 
observational studies of AM1 practices and outcomes but do not include the clinical details 
present in the medical record abstracts. The enrollment files include comprehensive all-cause 
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intended to improve blood flow to the heart. The two common revascular- 
ization procedures are angioplasty (PTCA, or percutaneous transluminal 
coronary angioplasty), which involves the use of a balloon (or stent, re- 
cently) at the end of a catheter to eliminate blockages, and bypass surgery 
(CABG, or coronary-artery bypass graft surgery), a major open-heart sur- 
gical procedure to bypass the area of blockage. 
Despite the importance of heart attacks for population health and the 
importance of these intensive procedures for health care resources use, the 
procedures have been studied in only a limited number of randomized clin- 
ical trials. Several trials examined the effectiveness of bypass surgery in the 
early 1980s and angioplasty in the following years. In general, these trials 
found limited mortality benefits in a few subgroups of patients treated. Tri- 
als of bypass surgery versus no intensive procedures included Brown et 
al. (1981),  Takekoshi, Murakami, and Nakajima (1983), and Koshal et 
al. (1988). Trials of angioplasty included Erbel et al. (1986), Simmoons et al. 
(1988), TIM1 Study Group (1989), and Zijlstra et al. (1993). But most of 
these studies focused primarily on the immediate use of angioplasty, rather 
than on its use at all during the episode of treatment for heart attack. Re- 
flecting  changes in expectations about treatment benefits, recent trials have 
focused on narrower questions about use of the intensive procedures, such 
as the timing of catheterization (e.g., Califf and TAM1 VA  Study Group 
1991), the choice between angioplasty and bypass surgery, and the use of 
catheterization in very narrow subsets of patients (e.g., VANQWISH Study 
Group 1998). 
Nonetheless, the procedures have become much more widely used in 
heart attack patients for several reasons. First, the equipment quality and 
personnel skill involved in the procedure has improved substantially since 
the time of the trials, leading to much lower complication rates. Second, tri- 
als on many types of heart disease patients, such as women and the elderly, 
were regarded as too costly to justify additional studies given the previous 
trial results. Third, as experience accumulated, fewer and fewer patients 
were willing to be randomized for such an important decision as an inten- 
sive cardiac procedure. As with many other intensive medical technologies, 
these heart procedures are now used in a much broader range of patients 
than have been explicitly supported by randomized trials. 
Consequently, these procedures have been studied frequently using ob- 
servational methods. In Japan, there have also been several observational 
studies on the effects of intensive procedures on patient outcomes, that is, 
by the Japanese Society of Interventional Cardiology. Studies based on di- 
rect comparisons of treated and nontreated patients have generally found 
that intensive cardiac procedures like bypass surgery were associated with 
significant and substantial mortality reductions in these additional pa- 
tients, even after accounting for observational difference. For example, us- 
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and Rubin (1984) estimate a large improvement in functional status and 
in survival for patients with heart disease undergoing bypass surgery. In 
contrast, observational studies using new statistical methods, such as in- 
strumental variables (IV; e.g., McClellan, McNeil, and Newhouse 1994; 
McClellan and Newhouse 1997; McClellan and Noguchi 1998,2001) and 
general method of moments (GMM; e.g., McClellan and Staiger 2000a,b) 
have found small mortality effects that appear to be due at least in part to 
other associated treatments. The estimation methods appear to matter for 
the results in this case, and the source of the discrepancy in the results-ei- 
ther in differences in biases or differences in the subpopulations included 
in  the effect estimates-is  unclear. These sorts of  inconsistencies have 
plagued observational studies of treatment effects and limited their rele- 
vance for clinical practice and policies intended to influence it. Either IV 
or GMM is appropriate for population-based data with enough variation 
among patients and medical facilities such as the CCP, but not for data 
with a small number of observations and little variation, like the data we 
collected in Japan for this project. 
First, therefore, we use a bivariate probit procedure in order to examine 
the effects of cardiac catheterization as a high-tech procedure on patient 
outcomes and hospital expenditures. Second, we will also focus on low-tech 
treatments during hospitalizations, such as aspirin, beta-blockers, calcium 
channel blockers, and smoking cessation. Unlike high-tech treatments, 
these drug treatments have been studied in a large number of randomized 
clinical trials  since the  1980s (e.g., Lewis, Davis,  and Archibald  1983; 
ISIS-2 Collaborative Group 1988; Kober et al. 1995; MERIT-HF 1999; and 
CIBIS-I1 1999). The recent  update  of  the  1999 ACC/AHA (American 
Heart Association/American College of Cardiology) guidelines originally 
released in 1996 collected scientific evidence regarding the benefits and risks 
of these drugs, including both randomized trial and observational studies. 
The ACC/AHA guidelines for AM1 patients recommend aspirin use and 
smoking cessation during hospitalization, and aspirin, beta-blockers, and 
angiotensin converting enzyme (ACE) inhibitors at discharge. The ACC/ 
AHA states that encouraging these procedures will contribute to improving 
survival probabilities in the population. This statement is consistent with 
conclusions from several studies based on the CCP (e.g., Jencks et al. 2000; 
Frances et al. 2000; Shilipak et al. 2001; Shlipak et al. 2002). 
Using the exclusion and inclusion criteria for these treatments from the 
ACC/AHA guidelines (table 7A. 1  ), we  will examine how many patients 
were  identified as good  candidates for  aspirin,  beta-blockers; calcium 
channel blockers; and smoking cessation during hospitalization and how 
they were actually treated.* 
2. For thrombolytic drugs-IV  nitrogen and ACE inhibitors-the  complete indicators for 
exclusion or inclusion criteria to determine ideal or good candidates are not available in our 
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7.3  Empirical Specification  and Measurements 
In this section, we explain our empirical specification for estimating the 
effects of high-tech and low-tech treatments after hospitalization on out- 
comes and medical expenditures and for investigating the variation in the 
quality of care across countries. Cardiac catheterization can be considered 
as the entry procedure for further intensive revascularization procedures. 
The mean and median durations between hospital admission and cathe- 
terization in our data are eight days and twenty-four hours, respectively. 
Thus, we use seven-day catheterization to measure the effects of high-tech 
procedures on outcomes and expenditure. 
We will apply a bivariate probit procedure for evaluating the impacts of 
seven-day catheterization on the following dichotomous dependent vari- 
ables: thirty-day  and one-year mortality,  and ninety-day and  one-year 
hospital  readmission  for  any cause. A  seemingly unrelated  regression 
method is used for the continuous dependent variables: ninety-day and 
one-year medical expenditures and length of stay from the first hospital 
admission3 (Maddala and Lee 1976; Maddala 1983; Greene 1993, 1998). 
We use these dependent variables as measures for evaluating the quality of 
care for AM1 patients. In addition to seven-day  catheterization, we include 
five low-tech procedures into our model as explanatory variables: use of 
thrombolytics, aspirin, beta-blockers, and ACE inhibitors and smoking 
cessation during hospital stay. We expect these low-tech procedures to be 
highly correlated with aggressive high-tech procedures. All regressions are 
controlled  for  patient  demographic  and  chart-based  comorbidity  and 
severity measures. 
There are a couple of major reasons for adopting a bivariate probit pro- 
cedure in this study: (a) we suspected that the simple least squares proce- 
dure would produce inappropriate estimates because the dependent vari- 
ables are binominal (0 or 1); (b) for estimating the effects of seven-day 
catheterization on patient outcomes and hospital expenditure, one single 
regression analysis including catheterization  as an explanatory variable 
will be inappropriate and statistically biased as whether a patient under- 
goes cardiac catheterization within seven days after admission is endoge- 
nous. Seven-day catheterization  would be highly correlated with patient 
characteristics and other drug use so that the independence among ex- 
planatory variables cannot be assumed to hold in the simple least squares 
method. Therefore, it is appropriate to assume a bivariate distribution for 
two probabilities: the likelihood a patient undergoes seven-day catheteri- 
zation and the likelihood a patient dies or is readmitted within a certain pe- 
riod after discharge. 
3. As regards the length of hospital stay, like hospital expenditure, ninety-day and one-year 
total durations of stay are ideal as measuring patient outcomes. However, the lengths of hos- 
pital stay after the first readmission are available only for limited number of patients in Japa- 
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The key regression formulas are the following: 
(1) 
(2) 
where E, -  N(0,  l),  E, -  N(0,  l), COV(E~,  E,)  = p; yT  and y: show unobserved 
underlying index determining seven-day catheterization and patient out- 
comes; y,  and y2  are the observed patterns of seven-day catheterization 
and patient outcomes; and, finally, XI  and X,  include patient demographic 
characteristics, comorbidity, severity, and drug treatments. The depend- 
ent variables, yT  and y;  themselves cannot be directly observed. However, 
with respect to regression formula (l),  y,  equals 1 if the patient underwent 
seven-day catheterization and 0 otherwise. Also, with respect to regres- 
sion formula (2),  y,  equals 1 if the patient dies or is readmitted to the hospi- 
tal within a certain period after discharge and 0 otherwise. The indepen- 
dent variables, X,  and X,,  include patient demographic characteristics; 
severity and comorbid measures; and drug use such as thrombolytics, as- 
pirin, beta-blockers, and ACE inhibitors; and smoking cessation during 
hospital  stay. The residuals  from the two regressions,  E,  and E,,  were 
assumed to have the standard normal distribution. In other words, we 
assumed the expected values were E(E,)  = E(E,)  = 0, and the distribu- 
tions were Var(E,) = Var(E,)  = 1. The covariance of E, and E,  was to be 
COV[E~,  EJ = p. We introduce the bivariate predicted probabilities as fol- 
lows: 
yT = p,X, + E,  y,  = 1 ifyT >  0,O otherwise 
y: = P,X, + E,  y, = 1 ify:  >  0,O otherwise, 
seven-day catheterization (y,  = 1) and the patient dies or is 
readmitted (y,  = 1) 
seven-day catheterization (y,  = 1) and the patient does not die or is 
not readmitted (y,  = 0) 
readmitted (y2  = 1) 
is not readmitted (y,  = 0) 
QO1: no seven-day catheterization (y,  = 0) and the patient dies or is 
aOo:  no seven-day catheterization (y,  = 0) and the patient does not die or 
The log-likelihood function to be maximized in terms of p,, P2, and p is 
(3)  In L(P,,  P2, PI = c  YlY, In @,I  + c  Y,(l -  v,)  In @lo 
Note that because the hospital expenditure variable is continuous, we will 
utilize a seemingly unrelated regression procedure that assumes a bivariate 
probability distribution based on a linear regression rather than the bi- 
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7.4  Data 
Charts were abstracted for 371 AM1 patients admitted to ten medical fa- 
cilities located in an urban area of Aichi prefecture in Japan. Charts were 
carefully reviewed by  research nurses and physicians, with all sampling 
taking place between January and December  1995. The CCP includes 
Medicare enrollees, most of whom are sixty-five years and older. The pop- 
ulation in this study was comparable, with 190 patients (out of  371) age 
sixty-five years and older. The median number of patients admitted to each 
medical facility within the study period was 23, and the median number of 
catheterizations performed was eighteen. We followed standardized pro- 
cedures  for  abstracting medical  records,  similar  to those  used  by  the 
Health Care Financing Administration (HCFA) for the CCP. The record 
abstracts contain over 100 comorbidity and severity measures. The CCP’s 
expert advisory panel believed that these measures collectively summarize 
all of the major associated diseases, functional status impairments, and as- 
pects of AM1 severity that would influence the appropriateness of major 
AM1 treatment decisions and health outcomes. 
For the U.S. sample, we extracted 889 patients from sixteen hospitals. 
These patients were chosen out of approximately 180,000 CCP patients 
with the goal of making the U.S. sample comparable to the Japan sample. 
First, we selected five metropolitan statistics areas (MSAs) in the United 
States with rates of AM1 incidence similar to Aichi prefecture (between 
190 and 200 per  100,000 per year). Second, because the Japanese data 
only includes catheterization facilities, we  excluded noncatheterization 
hospitals (defined as hospitals that performed fewer than four catheteri- 
zations per year, the minimum number of catheterizations in the Japanese 
data). Thus, we extracted patients hospitalized in medical facilities pro- 
viding care with a similar level of technology in both countries. The me- 
dian number of CCP patients admitted to each hospital was eighty, and 
the median number of catheterizations performed at each hospital was 
thirty-three. Therefore, the number of patients and catheterizations per 
year in each hospital are several times larger in the United States. Sam- 
pling for the CCP occurred between April 1994 and July 1995 at essen- 
tially all hospitals in the United States, which is slightly different than the 
sampling  time  frame  for  the  Japanese  data. A  major  technological 
change-the  aggressive use of stent for PTCA or percutaneous coronary 
intervention (PC1)-occurred  in 1996 to 1997 in both countries, but the 
difference in time frames between the studies would not likely affect our 
results. Note that all the results obtained in this study are not necessarily 
generalizable because all the included hospitals are high-volume catheter- 
ization hospitals in urban areas. Also, note that the following statistical 
analyses of the CCP data are weighted by the number of patients in each 
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7.4.1  Patient Heterogeneity 
Table 7.1 illustrates the data elements in record abstracts from the CCP 
and Japanese data. This highlights some of fundamental problems in ob- 
servational  analyses based  on direct comparisons of treated  and non- 
treated patients. The table shows that the fraction of patients who under- 
went catheterization was approximately 45 percent in the United States 
and 78 percent in Japan. In the United States, catheterized patients were 
more likely to be younger and male, although the gender gap of treatments 
in the Japanese data is trivial. This may explain why there are so few stud- 
ies on the effect of gender on disease outcomes in Japan (e.g., Oe et al. 2002) 
or on treatment differences by  gender. In contrast, the gender gap in the 
treatment of coronary artery disease in the United States has been widely 
explored, although the reasons for the disparity remain inconclusive. (See, 
for example, Harrold et al. 2003; Bertoni et al. 2004; Weisz, Gusmano, and 
Rodwin 2004; Hochman et al. 1999; and Rodwin and Gusmano 2002.) De- 
mographic differences between treated and nontreated patients were de- 
scribed in previous studies based on less-detailed administrative records 
(e.g., McClellan, McNeil, and Newhouse 1994). Rates of some of the ad- 
ditional comorbidity and severity variables are also reported; treated and 
nontreated patients differ substantially in almost all of these dimensions, 
with  catheterized  patients  generally appearing  to be  in  better  health. 
Catheterized patients are much more likely than noncatheterized patients 
to be in good functional status (e.g., independent mobility). Also, they are 
generally less likely to have serious comorbid diseases like prior heart fail- 
ure, posterior vitreous detachment (PVD) or claudication, cerebral hem- 
orrhage, renal failure, and liver failure. The only exception is in the preva- 
lence of chest pain due to heart problems prior to the AMI, which is  a 
common indication for catheterization. Patients undergoing catheteriza- 
tion were much more likely to be alert and oriented on initial admission, to 
have no signs of serious heart failure (e.g., high heart rate or low blood 
pressure), and to have good kidney function as shown by  nonelevated 
blood nitrogen. With literally hundreds of variables that describe patient 
characteristics, interpreting the cumulative consequences of the differences 
for outcomes is difficult. For this reason, we constructed a summary indi- 
cator of disease comorbidity and severity. The Killip class is based on a 
number of clinical characteristics related to the extent of heart failure in an 
AM1 patient. This measure has been shown to provide a reliable predictor 
of short-term AM1 mortality. Killip classes 3 and 4 indicate moderate and 
severe heart failure, while Killip classes 1 and 2 indicate relatively mild 
heart failure. As table 7.1 shows, catheterized patients in both countries 
are much more likely to be in the lowest Killip class. These results provide 
clear evidence that patient heterogeneity is a fundamental challenge for Table 7.1  Key variable definitions and summary statistics for patient characteristics 
United States  Japan 
Total  No 7-day cath  7-day cath  Totdl  No 7-day cath  7-day cath 
Standard  Standard  Standard  Standard  Standard  Standard 




Age in years 
Severity measures 
Killip ckdss 1 
Killip class 2 
Killip class 3 
Killip class 4 
Treatment measures 
Catheterization during stay 




1  -year catheterization 





































































































(0.488)  0.332  (0.472)  0.333  (0.475)  0.331  (0.472) 
(0.270)  ~ 
(8.469)  73.379  (6.494)  75.470  (7.766)  72.266  (5.416) 
-  -  -  -  ~ 
(0.477)  0.771  (0.421)  0.600  (0.494)  0.867  (0.341) 
(0.310)  0.052  (0.223)  0.091  (0.290)  0.031  (0.173) 
(0.412)  0.131  (0.338)  0.236  (0.429)  0.071  (0.259) 






















































































:continued) Table 7.1  (continued) 
United States  Japan 
Totdl  No 7-day cath  7-day cath  Total  No 7-day cath  7-day cath 
Standard  Standard  Standard  Standard  Standard  Standard 
Mean  deviation  Mean  deviation  Mean  deviation  Mean  deviation  Mean  deviation  Mean  deviation 
Cardiac bypass surgery during 
1  -day cardiac bypass surgery 
7-day cardiac bypass surgery 
30-day cardiac bypass surgery 
90-day cardiac bypass surgery 
1-year cardiac bypass surgery 
Angiotensin-converting-enzyme 
Warfarin during stay 
Heparin >  4000 U during stay 
Thrombolytics during stay 
Aspirin during stay 
IV nitrogen during stay 



































































































































































(0.279) Angio tensin-converting-enzyme 
Warfarin at discharge 
Aspirin at discharge 
Beta-blocker at discharge 
Calcium channel blocker 
Smoking cessation during stay 
Outcome measures 
Died within 1 day 
Died within 7 days 
Died within 30 days 
Died within 1 year 
In-hospital death from 1st 
90-day total expenditure 
1  -year total expenditure in 
90-day readmission 
1  -year readmission 
Length of stay from 1st 
hospital admission 






0.321  (0.467) 
0.199  (0.399) 
0.668  (0.471) 
0.314  (0.464) 
0.428  (0.495) 
0.074  (0.262) 
0.066  (0.249) 
0.143  (0.350) 
0.198  (0.399) 
0.318  (0.466) 
0.182  (0.386) 
11841.520  (13761.830) 
0.370  (0.484)  0.270  (0.445)  0.297  (0.459)  0.236  (0.429)  0.330  (0.473) 
0.192  (0.395)  0.206  (0.405)  0.153  (0.361)  0.000  (0.000)  0.229  (0.423) 
0.571  (0.496)  0.770  (0.422)  0.686  (0.465)  0.482  (0.504)  0.784  (0.413) 
0.259  (0.439)  0.371  (0.484)  0.083  (0.276)  0.073  (0.262)  0.088  (0.284) 
0.484  (0.500)  0.368  (0.483)  0.404  (0.492)  0.382  (0.490)  0.414  (0.495) 
0.065  (0.247)  0.087  (0.282)  0.079  (0.272)  0.138  (0.351)  0.029  (0.171) 
0.102  (0.303)  0.018  (0.134)  0.042  (0.201)  0.061  (0.240)  0.032  (0.177) 
0.201  (0.401)  0.066  (0.248)  0.068  (0.253)  0.106  (0.310)  0.048  (0.215) 
0.278  (0.448)  0.092  (0.289)  0.121  (0.327)  0.197  (0.401)  0.081  (0.273) 
0.445  (0.497)  0.150  (0.357)  0.289  (0.455)  0.318  (0.469)  0.274  (0.488) 
0.250  (0.433)  0.092  (0.289)  0.158  (0.366)  0.288  (0.456)  0.089  (0.285) 
9427.900  (12093.490)  15059.680  (15141.540)  24,503  (17,207)  14,699  (12.054)  28,354  (17,560) 
15180.470  (17928.130)  13056.990  (1  6696,120)  1801  1.780  (19107.91  0)  28,938  (1  7.977)  21,330  (1  5,760)  31,790  (18,102) 
0.292  (0.455)  0.294  (0.456)  0.289  (0.454)  0.425  (0.498)  0.250  (0.444)  0.491  (0.505) 
0.421  (0.494)  0.438  (0.497)  0.397  (0.490)  0.712  (0.456)  0.450  (0.510)  0.811  (0.395) 
8.514  (100.819)  7.902  (97.621)  9.332  (103.970)  32.314  (30.267)  36.424  (45.256)  30.144  (17.786) 
889  508  38 1  190  66  124 
Notes: For United States, tables gives weighted mean values by the number of patients in each metropolitan statistical area. PPP = purchasing power parity, 176  Noguchi, Masuda, Kuzuya, Iguchi, Geppert, and McClellan 
observational studies that rely on direct comparisons of catheterized and 
noncatheterized patients. 
7.4.2  Treatment Heterogeneity 
Table 7.1 also shows that outcomes may differ between catheterized and 
noncatheterized  patients  due  to differences in  treatments  other  than 
catheterization. Our medical reviews include substantial information on a 
range  of  treatments  besides cardiac procedures,  especially drug treat- 
ments, which might influence outcomes. 
First, regarding high-tech treatments, the table shows that Japanese pa- 
tients tend to be more aggressively treated than the CCP patients. Among 
the CCP patients, 45 percent receive an angioplasty and 17 percent are 
catheterized, whereas the rates of these intensive treatments among the 
Japanese patients are 78 percent and 54 percent, respectively. Also, the tim- 
ing of clinical decision making for intensive procedures is much earlier in 
Japan than in the United States. Within twenty-four hours after hospital 
admission, almost 60 percent of patients in Japan were treated by catheter- 
ization, and 40 percent were treated with angioplasty; the comparable rates 
among CCP patients were only 17 percent and 8 percent, respectively. Our 
findings are consistent with previous studies showing that, compared to 
other developed countries, angioplasty has rapidly spread in Japan since 
it was first performed in 1980 (Sasakuri et al. 1997), and rates of PCI fol- 
lowing cardiac catheterization  are much higher in Japan  (e.g., Nippon 
Shinkekkan Intervention Gakkai Gakujutsu Iinkai 1993; Endo and Ko- 
yanagi 1994).  These previous studies also found that the ratio of angioplasty 
to cardiac bypass surgery is much higher in Japan. Our results are consis- 
tent with the previous results. We find that in the United States, 17 percent 
of patients were treated with angioplasty and 11 percent with bypass sur- 
gery, whereas the rates in Japan were 54 percent and only I  percent, re- 
~pectively.~  This extremely high ratio may be caused by  alarmingly high 
mortality from cardiac bypass surgery in the early stage of diffusing bypass 
technology in Japan (Sezei et al. 1970; Hayashi 1972; Asada et al. 1970) and 
more-attractive  reimbursement  for  angioplasty  than  bypass  surgery 
(Yoshikawa et al. 2002). 
Table 7.1 shows that patients who receive catheterization are more likely 
to receive a variety of other beneficial treatments in both countries. For ex- 
ample, during hospitalization they are much more likely to receive aspirin, 
which has been directly shown to reduce AM1 mortality (92 versus 63 per- 
cent in the United States and 78 versus 57 percent in Japan); they are more 
4. Previous studies (e.g., Nippon Shinkekkan Intervention Gakkai Gakujutsu Iinkai 1993; 
Endo and Koyanagi 1994) found that the ratio of angioplasty to bypass surgery is almost 5 to 
1, on average, but it varies among regions-4  to 1 in the eastern region of Japan and 8 to 1 in 
the western region. Therefore, the results based on the data from collaborative medical cen- 
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likely to receive thrombolytic or “clot-busting” drugs, which help dissolve 
the blood clot that causes the AM1 (23 versus 10 percent in the United 
States and 37 versus 21 percent in Japan); and they are more likely to re- 
ceive beta-blockers, which reduce the workload of the heart (57 versus 32 
percent in the United States and 8 versus 2 percent in Japan). Catheterized 
patients in both countries are also more likely to receive protective drug 
treatments after discharge that might improve long-term  outcomes, in- 
cluding aspirin and beta-blockers. But, in the United States, catheterized 
patients are slightly less likely to receive ACE inhibitors both during hos- 
pitalization and at discharge. These drugs are used primarily in patients 
with chronic heart failure (that is, patients who  have had more severe 
AMIs). In the Japanese data, catheterized patients are more likely to re- 
ceive them. In addition to these observed treatments, there are probably 
many  other  unobserved  treatments  and environmental  influences that 
might differ for catheterized versus noncatheterized patients and also con- 
tribute to outcome differences. 
7.4.3  Outcome Differences 
The final section of table 7.1 shows the consequences of catheterization 
as well as of these differences in individual characteristics and treatments 
for patient outcomes. Not surprisingly, the differences are large, yet these 
differences are much larger in the United States than Japan. Noncatheter- 
ized patients have one-year mortality rates 3 1  percentage points higher (46 
versus 15 percent) in the United States and 5 percentage points higher (32 
versus 27 percent) in Japan. Large mortality differences appear at one day 
(10 percent versus 2 percent in the United States and 6 percent versus 3 
percent in Japan) and increase steadily. These results suggest that catheter- 
ized patients have much lower mortality risks for all time intervals after 
AM1 than noncatheterized patients, but many other treatment differences 
may also contribute to the observed mortality differences. 
Although patients we focus on in this study are sixty-five and older and 
so are covered by  similar fee-for-service reimbursement systems in both 
countries, medical facilities in the Japanese data have weaker incentives for 
cost containment. One-year hospital expenditures, calculated using pur- 
chasing power parity, are higher for catheterized patients in both countries 
($18,011 versus $13,057 in the United States, $31,790 versus $21,330 in 
Japan). In general, the mean length of stay from the first hospital admis- 
sion is much shorter in the United States than in Japan (nine days versus 
thirty-two days). The longer length of hospital stay is one of the major 
causes of higher expenditures in Japan versus the United States. Further, 
seven-day catheterization has a reverse effect on the length of hospital stay 
between the CCP and Japanese patients. A CCP patient who undergoes an 
intensive procedure tends to stay in a hospital longer by approximately one 
day compared to the one who does not, while the hospital stay for a patient 178  Noguchi, Masuda, Kuzuya, Iguchi, Geppert, and McClellan 
in Japan is six days shorter. In our Japanese data, almost 60 percent of pa- 
tients underwent catheterization immediately after hospital admission. Pa- 
tients who do not undergo seven-day catheterization tend to suffer from 
more-severe heart attacks so that they are expected to stay in hospitals 
longer than catheterized patients, probably for clinical reasons. 
Like the health  outcome differences, however, these differences may 
simply reflect differences in patient  characteristics  or treatments other 
than the effect of catheterization. For example, because catheterized pa- 
tients are more likely to survive, they may have higher medical expendi- 
tures independent of catheterization use. Hence, we have to examine care- 
fully the  effects of  seven-day catheterization  on patient  outcomes and 
hospital expenditures, controlling for both patient and treatment hetero- 
geneity. 
7.5  Results 
Table 7.2 shows the marginal effects calculated based on the results of a 
bivariate probit analysis for each country. Panel A of table 7.2 indicates the 
results of regression equation (l),  with the binomial dependent variable 
equaling 1 when a patient underwent seven-day catheterization and 0 oth- 
erwise. Also, panel B shows the results of regression equation (2), with the 
binomial dependent variable equaling 1 when a patient died or was read- 
mitted to the hospital within a certain period after discharge and 0 other- 
wise. Each panel in table 7.2 shows only the treatment variables of interest, 
and all regressions include controls for detailed patient characteristics. 
7.5.1  Effects of High-Tech Procedure on the Quality of Care 
First, we  discuss the effects of high-tech interventions on patient out- 
comes, hospital expenditures, and length of stay. As shown in the panel B 
of  table 7.2, both the  CCP and Japanese  data suggest  that  seven-day 
catheterization contributes to a decrease the probabilities of both mortal- 
ity and readmission for all time intervals, although the impacts on ninety- 
day readmission is not statistically significant in either country. The effects 
of seven-day catheterization on mortality are much larger in the United 
States than in Japan. However, the difference in  impacts of  seven-day 
catheterization  on thirty-day versus one-year mortality rates are almost 
the same in both countries (approximately 6 percentage points  at one 
year). Further, seven-day catheterization decreases one-year readmission 
rates by 21 and 32 percentage points for the CCP and Japanese patients, re- 
spectively. 
Figures  7.1  and  7.2  illustrate  the  adjusted  probability  of  seven-day 
catheterization  and patient outcomes by  biprobit  model in the United 
States and Japan, respectively. These figures show that the adjusted proba- 
bilities of  thirty-day and one-year mortality  conditional on seven-day Table 7.2  Effects of seven-day catheterization on patient outcomes by bivariate probit analysis 
United States"  Japan 
90-day  I-year  Length  90-day  I-year  Length 
readmission readmission  of  readmission readmission  of 
30-day  I-year  forany  forany  90-day  I-year  hospital  30-day  I-year  for any  for any  90-day  I-year  hospital 
mortality  mortality  cause  cause  expenditure  expenmture  stay  mortality  mortality  cause  cause  expenditure  expenditure  stay 
Thromholytics use 
during stay 

































































































































A. First equation for 7-day cath 
0.077**  0.068**  1.124** 
(0.426)  (0.041)  (0.074) 
0.251***  0.249***  0.731*** 
(0.376)  (0.037)  (0.079) 
0.074***  1.221*  0.042 
(0.322)  (0.031)  (0.160) 
0.014  0.039  -0.094 
(0.320)  (0.031)  (0.084) 
-0.045  0.010  -1.538** 
(0.567)  (0.062)  (0.232) 
B. Secondequtwn  forpatient outcomes 
5160.540***  5634.330***  1.645***  -0.141*** 
(1035.491)  (1339.860)  (0.552)  (0.071) 
-981.344  -1108.269  1.085*  -0.241 
(1316.630)  (1710.970)  (0.677)  (0.043) 
1364.137  3902.250***  0.897*  -1.178*** 
(1 189,678)  (1415.314)  (0.618)  (0.059) 
598.790  -30.244  0.097  -0.405 
(996.926)  (1306.556)  (0.518)  (0.072) 
335.949  806.030  2.625***  0.610 
(987.849)  (1297.685)  (0.517)  (0.058) 
-2682.285*  -1695.446  -0.194  -0.122 
(1750.316)  (2287.076)  (1.021)  (0.095) 
0.791 
(0.023) 


























































































-0.320**  2145.305 
(0.122)  (1565.115) 
0.769  -5074.712** 
(0.072)  (1563.686) 
0.641*  -2149.844 
(0.105)  (1682.250) 
0.102  525.981 
(0.127)  (3418.078) 
-0.080  -1653.425 
(0.094)  (1700.296) 
-12.649  -4844.199 
(0.160)  (4523.262) 
0.170** 
(1.850) 



























~  ~  ~ 
Notes: Standard errors in parentheses. For biprohit analyses, the marginal effect of each explanatory variable is calculated as  f(p,X,) .  coefficient  for panel A  andf(PIXJ  . coefficient for panel B.  Each equation 
is controlled for patient demographic characteristics, comorbidity and severity measures. For medical expenditure, seemingly unrelated regression method is used, since dependent variables are continuous. 
"For United States, weighted biprobit by the number of  patients in each metropolitan area. 
***Significant  at the 5 percent level. 
**Significant at the 10 percent level. 
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4  (7-day cath; patient outcornel) 
84 (no  7-day cath:  patient outcome=l) 
04 (7-day ~8th;  paucnt autcame=01 
Em  (no  7-day cath: patient outcome=01 
Probability of patient outcome 
Fig. 7.1 
catheterization by biprobit model (United States) 
Adjusted probability for patient outcomes conditional on seven-day 
Probability of patient DU~CO~E 
Fig. 7.2  Adjusted probability for patient outcomes conditional on seven-day 
catheterization by biprobit model (Japan) 
catheterization are approximately 1 percent and 2 percent for CCP patients 
and 1 percent and 11 percent for Japanese patients. The adjusted proba- 
bilities of thirty-day and one-year readmission conditional on seven-day 
catheterization are approximately  3 percent and 9 percent for CCP patients 
and 2 percent and 36 percent for Japanese patients. Therefore, among A Comparison of the Quality of Health Care in the U.S. and Japan  181 
those who undergo intensive procedures within one week, the risks of dy- 
ing and being readmitted to a hospital are about the same in both countries 
over a relatively short time interval, but they become much larger at one 
year after the first hospital admission in the Japanese data compared to the 
CCP patients. On the other hand, the adjusted probabilities of thirty-day 
and one-year mortality conditional on no seven-day catheterization are 
approximately 23 percent and 26 percent for CCP patients and 0 percent 
and 0 percent for Japanese patients. As regards adjusted probabilities of 
thirty-day and one-year readmission conditional on no seven-day cath- 
eterization, they are approximately 39 percent and 15 percent for CCP pa- 
tients and 0 percent and l percent for Japanese patients. Thus, among those 
without  seven-day catheterization,  the risks of  dying and readmission 
are much larger in the CCP patients than the Japanese patients for any time 
interval, though the adjusted probability of readmission for the CCP pa- 
tients without seven-day catheterization are dramatically improved from 
thirty days through the one-year time interval. 
These results could be affected by the difference in the timing of clinical 
decision making for intensive procedures between both countries. The ag- 
gressive and quick clinical choice of intensive procedures (Sasakuri et al. 
1997; Nishida, Endo, and Koyanagi 1997) tends to improve patients’ out- 
comes over shorter intervals, while it may lead to increased risks over longer 
intervals. On the other hand, over all intervals, the CCP patients without in- 
tensive procedures face much higher risks of death and readmission, com- 
pared to Japanese patients without seven-day catheterization. 
After adjusting for patient chart-based characteristics, seven-day cathe- 
terization increases one-year hospital expenditures by $5,634 in the United 
States and by $3,028 in Japan. The significantly positive impacts of such 
high-tech treatments may partially account for the current high health care 
costs in both countries. The influence of a high-tech treatment on hospital 
expenditures is much larger for the CCP patients. However, note there are 
few  observations  for which  hospital expenditure data are available in 
Japan, which makes it difficult to make the correct clinical policy implica- 
tions. On the other hand, seven-day catheterization tends to have an op- 
posite effect on the length of hospital stay in the two countries. High-tech 
treatments increase the length of stay from the first admission by about two 
days for the CCP patients and decrease it by nine days for Japanese pa- 
tients, which is consistent with the results from the descriptive statistics. 
Adjusting for patient  and treatment  heterogeneity tends to enlarge the 
effect of intensive procedures on Japanese patients’ length of stay, implying 
that unobserved factors such as other patient characteristics and medical 
centers cost constraint incentives affect the results. 
7.5.2  Effects of Low-Tech Treatments on the Quality of Care 
Similar to table 7.1, panel A in table 7.2 shows that drug use is highly cor- 
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bolytics, aspirin, and beta-blockers during a hospital stay have signifi- 
cantly positive correlations with seven-day catheterization. We  also ob- 
serve that, for Japanese patients, thrombolytics and aspirin use (but not 
beta-blockers) are positively correlated with high-tech treatments. Inter- 
estingly, smoking cessation is negatively related to seven-day catheteriza- 
tion in Japan. This suggests that those who are treated by intensive proce- 
dures are more likely to receive some low-tech treatments, and there exists 
treatment heterogeneity among patients. In order to adjust for the hetero- 
geneity, we apply a bivariate probit procedure in this study. We observe that 
correlations calculated based on the covariance of residuals between the 
first and second equations, COV(E,,  EJ  = p, are statistically significantly 
different from 0 for the CCP patients, but that this is not the case for Japan- 
ese patients. This implies that the effect of treatment heterogeneity is much 
larger among the CCP patients. 
As regards the effects of drug use on patient outcomes, aspirin use is seen 
to decrease thirty-day mortality rates by  approximately 80 and 120 per- 
centage points in the United  States and Japan, respectively. The use of 
beta-blockers and ACE inhibitors also contributes to a decrease in the 
CCP patients’ readmission rates, but this is not the case for Japanese pa- 
tients. Rather, using beta-blockers and aspirin has a positive effect on one- 
year mortality and readmission rates, respectively, in the Japanese data. 
For the CCP patients, aspirin use seems to increase one-year hospital ex- 
penditures by $3,900 and the length of hospital stay by about one day. In 
contrast, it is interesting that aspirin use dramatically decreases one-year 
hospital expenditure in Japan. Also, use of thrombolytics contributes to a 
decrease in both ninety-day and one-year medical expenditures. In both 
countries, ACE inhibitor use tends to length the duration of hospital stay. 
Although most effects of drug use are not statistically significant and 
vary among patient outcomes as dependent variables, they appear to be 
more significant for CCP patients than for Japanese patients. Next, we ex- 
amine which patients can be defined as good candidates for receiving as- 
pirin, beta-blockers, no calcium channel blockers, and smoking cessation 
during their hospitalization and how they are actually treated. Patients are 
defined as good candidates according to exclusion and inclusion criteria 
from the ACC/AHA guidelines (table 7A. 1). This tests the appropriateness 
of the low-tech treatments. Note that we define ideal or good candidates for 
not  receiving  calcium  channel  blockers, as many  studies demonstrate 
harmful impacts on AM1 patients and their use has been decreasing in the 
United States (Rogers et al. 1996; McClellan et al. 2001). 
Table 7.3 summarizes the fraction of patients who are ideal or good can- 
didates for each drug based on clinical records and the probability that 
ideal or good candidates were actually treated. Figure 7.3 illustrates the 
probability, among ideal or good candidates, of receiving various treat- 
ments. Table 7.3 shows that the rates of ideal or good candidates vary Table 7.3  Ideallgood candidates for medications  during stay 
Variable 
United States  Japan 
Standard  Standard 
Mean  deviation  Mean  deviation 
Ideallgood candidate for aspirin 
Actually treated by aspirin 
IdeaVgood candidate for beta-blocker 
Actually treated by beta-blocker 
IdeaUgood candidate for no calcium channel blocker 
Actually treated by calcium channel blocker 
Ideallgood candidate for smoking cessation 
Actually treated by smoking cessation 
Candidate for CLASS I 
Actually treated by catheterization 
Candidate for CLASS IIa but not CLASS I 
Actually treated by catheterization 
Candidate for CLASS IIb only 
Actually treated by catheterization 
0.481  (0.500)  0.684  (0.466) 
0.799  (0.401)  0.732  (0.445) 
0.256  (0.437)  0.637  (0.482) 
0.408  (0.493)  0.088  (0.284) 
0.328  (0.470)  0.826  (0.380) 
0.421  (0.495)  0.426  (0.496) 
0.127  (0.333)  0.405  (0.492) 
0.372  (0.485)  0.179  (0.390) 
0.408  (0.492)  0.121  (0.327) 
0.554  (0.498)  0.783  (0.422) 
0.341  (0.474)  0.879  (0.327) 
0.356  (0.480)  0.778  (0.417) 
0.096  (0.294)  0.000  (0.000) 
0.387  (0.490)  0.000  (0,000) 
Number of observations  974  190 
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Fig. 7.3  Probability of being actually treated by medications  among ideal or good 
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widely between the two countries. Note that the disparity between the two 
countries in the fraction of individuals who are ideal or good candidates 
may be caused by missing information on exclusions and inclusion criteria. 
For aspirin, beta-blockers, no calcium channel blockers, and smoking ces- 
sation, the rates of ideal or good candidates tend to be much higher for 
Japanese patients than for CCP patients: 68 percent versus 48 percent, 64 
percent versus 26 percent, 83 percent versus 33 percent, and 41 percent 
versus 13 percent, respectively. The fraction of patients actually treated, 
among those identified as ideal or good candidates, is very alike, except the 
use of beta-blockers and smoking cessation. 
For Japanese patients, the underuse of beta-blockers and smoking ces- 
sation, relative to CCP patients, is noticeable, although the fraction of pa- 
tients identified as ideal or good candidates tends to be large in Japan. Pre- 
vious studies have explained the underuse of beta-blockers in Japan in 
various ways. Provocative vasomotor studies of Japanese patients found a 
higher incidence of inducible spasm and greater vasoconstriction of non- 
spastic segments than Caucasian studies (Beltrame, Sasayama, and Maseri 
1999; Pristipino et al. 2000). Therefore, in Japan, cardiologists may avoid 
using beta-blockers that could lead to an incidence of inducible spasm in 
order to avoid unnecessary  critical complications. On the other hand, 
Wang and Stafford (1998) emphasized the effects of nonclinical factors on 
beta-blocker use, such as age, unnecessary fear of complications without 
medical evidence, and regional and physicians’ characteristics. Also, Wang 
and Stafford (1998) pointed out that uninsured patients are more likely to 
undergo beta-blocker treatments that cost much less than other treatments 
in the United States. Because we focus on elderly patients at age sixty-five 
and older in this study, both CCP and Japanese patients are reimbursed by 
similar fee-for-service reimbursement systems in both countries. There- 
fore, the underuse of beta-blockers would be expected partly because of the 
weaker incentives for cost containment in Japan. 
Finally, compared to drug use, it would be difficult to justify criteria for 
identifying ideal or good candidates for high-tech treatments. However, 
according to guidelines by ACC/AHA (table 7A. l),  we define three types 
of candidates for catheterization: usually indicated, always acceptable and 
considered useful/effective (CLASS I); acceptable, of uncertain efficiency 
and may be controversial, weight of evidence in favor of usefulness or effi- 
cacy (CLASSIIa); and acceptable, of uncertain efficiency and may be con- 
troversial, not well established by evidence, can be helpful and probably 
not harmful (CLASSIIb). In the data, almost all patients are classified into 
either CLASS I or CLASSIIa. While the fraction of patients identified as 
CLASS I, that is, relatively ideal candidates, is higher for the CCP than 
Japanese patients (41 percent versus 12 percent), the fraction in CLASS- 
IIb, that is, good candidates, is higher for Japanese patients (88 percent ver- 
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figure 7.3 shows that Japanese patients are 1.5 to 2 times as likely to be 
catheterized than the CCP patients. 
Therefore, we conclude that the patterns of ideal or good candidates for 
drug use according to ACC/AHA guidelines are very alike between two 
countries. The CCP patients are more aggressively treated by beta-blockers 
than Japanese patients, and we observe that collaborative medical centers 
in the data tend to perform intensive procedures more often. 
7.6  Discussion 
The CCP is the first major undertaking of the Health Care Quality Im- 
provement Program  (HCQIP) from  1992 to 1998 administered  by  the 
HCFA. Under this project, peer review organizations in all states encour- 
aged health care providers to improve their systems of care for given qual- 
ity indicators for patients with AMI.  The new data collected by the HCQIP 
show that the quality of care for each clinical indicator varies from state to 
state and region to region. As regards AMIs, the data suggest that pre- 
scribing beta-blockers and aspirin for patients who have had a heart attack 
would be a course of action that could save hundreds to thousands of lives 
each year. One sign of the success of the CCP pilot project in Alabama, 
Connecticut, Iowa, and Wisconsin was an increase in the use of  beta- 
blockers for heart attack patients, following dissemination of the study’s re- 
sults, from 47 percent to 68 percent (Centers for Medicare and Medicaid 
Services 2000). 
The HCQIP and the CCP are considered models of public health policy. 
The HCQIP identified twenty-four  process-of-care  measures5 that  are 
strongly supported by clinical science and are widely accepted standards of 
care. These standards relate to primary prevention, secondary prevention, 
or the treatment of the six medical conditions including AMI, breast can- 
cer, diabetes, heart failure, pneumonia, and stroke. Therefore, the purpose 
of this study is to help improve health care policies in Japan where there has 
not yet  been established a system for collecting nationwide-individual- 
level clinical data. 
We create a database comparable to the CCP, and we focus our investi- 
5. For measurements indicating the quality of care for patients with AMI, the following in- 
dexes are used: administering aspirin to a beneficiary within twenty-four hours of the benefi- 
ciary’s admittance to a hospital (national median is 84 percent); prescribing aspirin when a 
beneficiary is discharged (national median is 85 percent); administering a beta-blocker to a 
beneficiary within twenty-four hours of the beneficiary’s admittance to a hospital (national 
median is 64 percent); prescribing beta-blockers when a beneficiary is discharged (national 
median is 72 percent); prescribing ACE inhibitors for patients with decreased left ventricular 
ejection fraction (national median is 71 percent); providing smoking cessation counseling to 
patients in the hospital (national median is 40 percent); the length of time before a patient re- 
ceives angioplasty in minutes (national median is 120 minutes); and the length of time before 
a patient receives thrombolytic therapy in minutes (national median is 40 minutes; Jencks et 
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gation on the variation in the quality of health care with respect to treat- 
ments and outcomes between the United States and Japan, controlling for 
chart-based detailed clinical information on elderly patients,  sixty-five 
years old and over, with AMI. Our main conclusions are as follows. 
First, we  found that there is significant heterogeneity among patients 
and in treatments that could influence the quality of care among elderly 
AM1 patients. In both the United States and Japan, catheterized patients 
were more likely to be  younger and in better health. Interestingly, the 
differences in treatment between men and women in Japan are trivial, as 
compared with treatment differences by gender in the United States. Also, 
Japanese patients tend to be more aggressively treated by angioplasty fol- 
lowing catheterization than the CCP patients. 
Comparison of national health systems may provide an insight into the 
effects of health system characteristics on the different treatment patterns 
in the United States and Japan. In the United States, inpatient care for 
older persons is  only partially  covered by  Medicare,  and beneficiaries 
could not receive prescription drug coverage for ambulatory care until re- 
cently, unless they had beforehand purchased supplemental insurance or 
hold coverage from a former employer. Medicare’s diagnosis-related group 
(DRG) payment system for hospitals fixes the payment at the time a patient 
is admitted to the hospital. Thus, since DRG was adopted in 1984, it might 
appear to  provide strong incentives to providers to limit costs. On the other 
hand, under the Japanese universal health insurance system, all medical fa- 
cilities are reimbursed on a fee-for-service  basis according to an official fee 
schedule (shinvyo hoshu).  Manipulation of the fee schedule serves as one of 
the primary mechanisms by which the Ministry of Health, Labour and Wel- 
fare regulates the supply of medical care, utilization rates, and aggregate 
health care expenditure. So far, in Japan, medical providers have no so- 
cioeconomic incentive to distinguish treatments for female from male pa- 
tients. Also, the upward trend in reimbursement for intensive cardiac treat- 
ment has translated into increased availability of the procedures and has 
motivated health care providers to utilize the high-tech procedures. 
Second, after adjusting for chart-based patient characteristics and vari- 
ation in treatments, we  observe that high-tech treatments would signifi- 
cantly improve patient outcomes and would increase hospital expenditures 
but that the effects are much larger for the CCP patients than the Japanese 
patients. 
Third, the aggressive and quick clinical choice to use an intensive proce- 
dure tends to improve patients’ outcomes in the shorter time interval, but 
it may lead to increased risks in the longer time period. 
Fourth, a CCP patient who undergoes an intensive procedure tends to 
stay in a hospital longer compared to the one who does not, while a patient 
who undergoes an intensive procedure in Japan is inclined to stay in the 
hospital for a shorter period. This apparent difference between Japan and A Comparison of the Quality of Health Care in the U.S. and Japan  187 
the United States may be a result of patient characteristics that are unob- 
served in the data, as well  as the economic incentives of  the respective 
health care systems. In the Japanese data, almost 60 percent of patients un- 
derwent catheterization immediately after hospital admission. Those who 
were not treated by seven-day catheterization are typically in very critical 
condition, leading to longer hospital stays. Also, under the universal cov- 
erage system in Japan, patients may have an economic incentive to stay 
longer in hospitals, particularly when they have no informal or unpaid 
caregivers (such as relatives) or sufficient financial resources to afford for- 
mal home care. Lately, in order to shorten the length of hospital stay and 
decrease medical expenditure, the Ministry of Health, Labour and Welfare 
raised the coinsurance rate for insured care services from 10 percent to 15 
percent when a patient occupies an acute-care bed for more than 180 days. 
Fifth, the patterns of ideal or good candidates according to ACC/AHA 
guidelines are very similar between the two countries, except beta-blocker 
use, smoking cessation, and catheterization. The CCP patients are more 
aggressively treated with beta-blockers and smoking cessation than Japa- 
nese patients, while we  observe that collaborative medical centers in the 
Japanese data tend to  perform intensive procedures more often. The under- 
use of beta-blockers in Japan was also found by previous studies and was 
attributed to clinical and socioeconomic causes. 
The data collected for this study may not be representative of the AM1 
population in Japan, as the data only contain patients admitted to high- 
volume and high-tech hospitals in a specific region. The statistically in- 
significant results mentioned in the preceding reveal the shortcomings of 
the current data. In order to overcome these shortcomings, our goal is to 
expand the hospitals and patients covered by this project in the future. Appendix 
Table 7A.1  Exclusions and inclusions criteria for various medications eligibility during hospitalization 
Variable  Definition 
IG-ASA  Good candidate for aspirin 
If XC31809 = 1 or XBSTOOL = 1 or XBLEED = 1 or 
XCOAGULP = 1 or XCI 1806 = 1 or XPLTl = 1 or 
XDXLIV = 1 or XULCER = 1 or XHEMAC = 1 or 
XYLCRE91= 1 or XCANCER = 1 or XTERMIL then 
excluded from ideal/good candidates for aspirin during 
hospitalization. 
IG-BBK  Good candidate for beta blocker 
If XSHOCK = 1 or XSYST = 1 or XCOND = 1 or 
XASTHMA = 1 or XBRDYPLS = 1 or XLVEFl = 1 or 
XLVEF2 = 1  or XCHF = 1 or XCOPD = 1 or 
XDEMENT = 1 or XC18004 = 1 or XC1225 = 1 or 
XCANCER = 1 or XTERMIL = 1 then excluded from 
ideal/good candidates of beta-blocker during 
hospitalization. 
Note: If XCOND1 = 1 or XCOND2 = 1 or XCOND3 = 1 
or XCOND4 = 1 then XCOND = 1 



























Allergy to aspirin 
Evidence of bleeding on admission or during hospitalization 
History of internal bleeding 
Coagulopathy (history of bleeding disorder or INR > 1) 
Warfarin on admission 
Platelet count < lO0K 
Chronic liver disease 
Peptic ulcer disease 
Hematocrit <  30% or hemoglobin (Hgb) < log 
Highest creatinine >  3mg/D1 
Metastatic cancer 
Terminal illness 
Hypotension or shock during hospitalization 
Systolic blood pressure on admission < IOOmmHg 
RBBB, any EKG, and left fascic block, any EKG 
RBBB and left fascic blocks 
RBBB, any EKG, and left fascic blocks 
RBBB and any left fascic blocks 
Conduction disorder 
Asthma during hospitalization 
Bradycardia or pulse on admission <  60 beatdmin. 
LVEF <  50% 
Pulmonary edema or CHF unless LVEF > 50% 
History of COPD 
Dementia 





Good candidate for no CA+ 
If XANYFIB = 1 or X@$CHST = 1 then excluded from 
and if XLVEFS = 1 or XSHOCK = 1 or CBKINCl = 1 or 
XCOND = 1 or XBRADY = 1 then included to ideaygood 
candidates of no calcium channel blockers with low LVEF 
during hospitalization. 
Ideal candidate for smoking cessation 
If XSMOKE = 1 then excluded from good candidates of 
smoking cessation during hospitalization. 
Candidate for CLASS I 
If CCLASSl = 1 then included in good candidates for 
CLASS I 
Candidate for CLASS IIa but not CLASS I 
If CHF = 1 or XLEVF4 = 1 or CHF = 1 or P-REVAC  = 1 
then included as ideal candidates for catheterization. 
Candidate for CLASS IIb only 
If CCLASSl = 1 then included in good candidates for 
CLASS IIb. 
















Antidepressant on admission 
Insulin on admission 
Mestastatic cancer 
Terminal illness 
Any atrial fibrillation 
Recurrent chest pain 
Inclusion: LVEF <  40% 
Inclusion: Hypotension or shock during hospitalization 
Inclusion: Pulmonary edema or CHF unless LVEF 2 SO% 
Inclusion: Conduction disorder 
Inclusion: Bradycardia 
Not a current smoker 
Inclusion: Recurrent chest pain or ischemia by stress test 
Inclusion: LVEF 5 40% 
Inclusion: CHF 
Inclusion: Pre-revascularization 
XQWAVEMI  Inclusion: Non Q wave Mis. 
Source; Ryan et al. (1999). 
“CLASS1 = usually indicated, always acceptable and considered useful/effective. 
bCLASSIIa = acceptable, of uncertain efficiency and may be controversial; weight of evidence in favor of usefulnesslefficacy. 
‘CLASSIIb = acceptable, of uncertain efficiency and may be controversial; not well established by evidence, can be helpful and probably not harmful. 190  Noguchi, Masuda, Kuzuya, Iguchi, Geppert, and McClellan 
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